Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.U3 Pharma, an antibody targeted cancer drug development affiliate of Daiichi Sankyo, has signed a research collaboration deal with AbCheck.
Subscribe to our email newsletter
AbCheck’s commercial multi antibody discovery platforms include AbSieve, which combines the company’s proprietary phage and yeast display technologies.
Under the deal, AbCheck will use AbSieve antibody discovery platform to deliver antibodies against an undisclosed number of U3 Pharma targets.
Having full rights to any antibodies selected, U3 Pharma will provide discovery fees and milestone payments to AbCheck.
Other financial details and deal terms have not been disclosed.
AbCheck managing director Volker Lang said the research collaboration with U3 Pharma, further underlines the quality of the company’s antibody discovery technologies and efficient processes that ensure the delivery of high quality GMP ready antibodies.
"Furthermore, this deal once again validates our exceptional business model, which has now been proven through partnerships with both pharma and biotech companies throughout the US and Europe," Lang added.
U3 Pharma CEO and managing director Shoji Hirashima said, "We believe we will identify good drug candidate antibodies more efficiently through this collaboration with AbCheck."